CGM sin recambio

ARMPatch, the new technology that allows glucose to be measured continuously and without frequent replacements.

More than 500 million people worldwide live with diabetes, making reliable continuous glucose monitoring (CGM) a critical unmet need. However, almost all commercial CGM devices rely on glucose oxidase enzymes, whose degradation within days or weeks requires frequent and costly replacements.

Although enzyme-free alternatives based on glucose-responsive hydrogels have shown great potential, their application remains limited by the shortcomings of the available readout systems: optical methods are susceptible to interference and pose potential toxicity issues, while ultrasound systems require implants and therefore invasive surgical procedures.

To overcome these limitations, researchers from Shenzhen Institute of Advanced Technology (SIAT) of the Chinese Academy of Sciences, Hong Kong Polytechnic University, and Korea Advanced Institute of Science and Technology (KAIST) developed the ARMPatch (Acoustic Readout Microneedle Patch), a wearable, enzyme-free glucose monitor based entirely on glucose-sensitive hydrogel microneedles.

The work, recently published in Science Advances, was led by Professor Meng Long of SIAT, together with Professor Su Zhongqing of Hong Kong Polytechnic University and Professor Jae-Woong Jeong of KAIST. Located between a conventional ultrasound probe and the skin, the ARMPatch functions as an acoustic interface that allows glucose monitoring without the need for enzymes, fluorescent dyes or specialized hardware.

Its hydrogel microneedles absorb interstitial fluid and swell in response to glucose variations, generating length changes that can be quantified in real time using any conventional ultrasound imaging system. This configuration makes the ARMPatch a simple accessory for existing ultrasound probes and eliminates the need for invasive procedures.

In laboratory tests, the device maintained stable glucose detection for 56 days, while in free-moving animal models it allowed continuous monitoring for 7 days. Measurements obtained using ultrasound showed a strong correlation with those obtained using a commercial glucometer.

These results position ARMPatch as the first documented approach for continuous glucose monitoring using conventional ultrasound imaging systems and open a new avenue for using this technology in portable biosensing applications.

SOURCE: Link

Le he dicho a la IA que lo investigue y me diga cuales son sus problemas:

1-Tiene un tiempo de respuesta de 30-60 minutos, o sea el tiempo que tardan las agujas de microgel en reaccionar a los cambios de glucosa en el líquido intersticial.

2-Luego para cada lectura tienes que acoplar una sonda de ultrasonidos.

Me parece una inutilidad total y absoluta.

@Sherpa41 said:

I have told the AI ​​to investigate it and tell me what its problems are:

1-It has a response time of 30-60 minutes, that is, the time it takes for the microgel needles to react to glucose changes in the interstitial fluid.

2-Then for each reading you have to attach an ultrasound probe.

It seems like total and absolute uselessness to me.

The original source says that up to 54 days, but in animals, it has only lasted 7. It doesn't seem like a big deal at the moment, but it is something, a replacement for oxidase.

Well, it says so in Pubmed in the scientific article itself. Almost at the beginning.

Link

"Glucose variations with millimolar resolution are obtained via ultrasound within a response time of 30 to 60 minutes."

Never, never trust what the media that "journalists" write say, only trust what the original scientific sources publish.

¡

Sherpa41 said:
@Sherpa41 said:

Well, it says so in Pubmed in the scientific article itself. Almost at the beginning.

Link

"Glucose variations with millimolar resolution are obtained via ultrasound within a response time of 30 to 60 minutes."

Never, never trust what the media that "journalists" write say, only trust what the original scientific sources publish.